Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

Actelion announces first quarter 2014 financial results

Jean-Paul Clozel, MD, CEO “I am very pleased
with Actelion’s good start into 2014. The launch
momentum for Opsumit, our new lead product in
Pulmonary Arterial Hypertension, is
very strong in all markets."

Jean-Paul Clozel, MD, CEO “I am very pleased
with Actelion’s good start into 2014. The launch
momentum for Opsumit, our new lead product in
Pulmonary Arterial Hypertension, is
very strong in all markets."